The Cancer Drug Isn’t Broken. Navrogen Thinks the Tumor Is Blocking the Signal

A tiny Pennsylvania biotech is betting that some antibody therapies fail for a surprisingly fixable reason: tumors throw molecular sand in the gears. Its answer is to redesign the antibody - or remove the sand.